Teva Pharmaceutical Industries Ltd. (TEVA)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Teva Pharmaceutical Industries Ltd. (TEVA)
Company Performance

Current Price

as of Oct 17, 2024

$17.96

P/E Ratio

N/A

Market Cap

$20.17B

Description

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Metrics

Overview

  • HQTel Aviv, TA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Generic
  • TickerTEVA
  • Price$17.96-0.33%

Trading Information

  • Market Cap$20.17B
  • Float99.99%
  • Average Daily Volume (1m)5,585,593
  • Average Daily Volume (3m)7,646,946
  • EPS-$0.39

Company

  • Revenue$16.30B
  • Rev Growth (1yr)7.21%
  • Net Income-$845.00M
  • Gross Margin48.58%
  • EBITDA Margin25.78%
  • EBITDA$1.07B
  • EV$35.28B
  • EV/Revenue2.16
  • P/EN/A
  • P/S1.25
  • P/B3.21
Documents
SEC Filings
8-K (2024-07-31)
8-K (2024-06-25)
8-K (2024-06-06)
8-K (2024-05-15)
8-K (2024-05-08)
8-K (2024-04-18)
8-K (2024-01-31)
8-K (2023-11-08)
8-K (2023-10-04)
8-K (2023-09-28)
8-K (2023-08-24)
8-K (2023-08-02)
8-K (2023-06-15)
8-K (2023-06-08)
8-K (2023-05-11)
8-K (2023-05-10)
8-K (2023-03-09)
8-K (2023-03-03)
8-K (2023-02-08)
10-Q (2024-07-31)
10-Q (2024-05-08)
10-Q (2023-11-09)
10-Q (2023-08-02)
10-Q (2023-05-10)
10-K (2024-02-12)
10-K (2023-02-10)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-08)
Earnings Report (2023-08-02)
Factset
Factset Business Description
Factset Street Account
Teva, Lilly dismiss patent lawsuit over Lilly's Emgality with prejudice (earlier, timing uncertain) (2023-11-26T08:36:01Z)
Teva presents data from Phase 4 UNITE study of AJOVY at World Congress of Neurology ($8.74, 0.00) (2023-10-17T05:33:38Z)
Teva Pharmaceutical publishes data from phase 3 RISE study in The Lancet Psychiatry; UZEDY significantly prolongs time to schizophrenia relapse ($8.76, 0.00) (2023-11-01T23:40:57Z)
Teva Pharmaceutical Industries upgraded to buy at UBS ($9.55, 0.00) (2023-11-27T05:24:17Z)
Teva Pharmaceutical Industries reports Q3 EPS $0.60 ex-items vs FactSet $0.61 [8 est, $0.56-0.68] ($9.04, 0.00) (2023-11-08T12:03:53Z)
Teva announces closing of collaboration deal to co-develop and co-commercialize asset TEV '574 with Sanofi (SNY) ($9.69, 0.00) (2023-11-30T13:32:36Z)
Teva announces approval of Forteo (teriparatide injection) generic in the U.S. ($8.76, 0.00) (2023-11-17T13:34:03Z)
Teva and Royalty Pharma collaborate to further accelerate Olanzapine LAI program ($8.68, 0.00) (2023-11-13T13:05:41Z)
StreetAccount Metrics Recap - Teva Pharmaceutical Industries Q3 Earnings ($9.04, 0.00) (2023-11-08T12:15:17Z)
StreetAccount Consensus Metrics Preview - Teva Pharmaceutical Industries Q3 Earnings ($9.11, +0.05) (2023-11-07T15:40:59Z)
Wikipedia
Teva_Pharmaceutical_Industries_Ltd.